vTv Therapeutics Enrolling People with Mild Alzheimer’s for Phase 3 Study of Oral Therapy

vTv Therapeutics Enrolling People with Mild Alzheimer’s for Phase 3 Study of Oral Therapy
vTv Therapeutics is recruiting patients for a large Phase 3 study, known as STEADFAST, assessing the drug azeliragon as a potential treatment for mild Alzheimer's disease (AD). Study participants will be randomly assigned to take either a 5 mg pill containing azeliragon once a day, or a placebo (sugar pill), for 18 months, with the drug's effectiveness determined through cognitive tests. Azeliragon is a small inhibitory molecule that blocks a receptor called RAGE (receptor of advanced glycation endproducts), which is thought to contribute to amyloid plaque deposits in the brain. Amyloid is a protein that, along with hyperphosphorylated tau, is believed to caus
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *